Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Infibeam Avenues Shatters Records! 93% Revenue Surge & AI Fintech Leap – HUGE Investor News!

Tech

|

Updated on 13 Nov 2025, 01:46 pm

Whalesbook Logo

Reviewed By

Abhay Singh | Whalesbook News Team

Short Description:

Infibeam Avenues Ltd reported its best-ever quarter, with gross revenue jumping 93% year-over-year to INR 1,964.9 crore for the September 2025 quarter. Profitability also rose, with PAT Margin up 42% to INR 64.9 crore. This growth is driven by its AI-focused digital payments, increased Total Payment Volume (TPV), and strategic sale of its Platform Business to subsidiary Rediff.com India Ltd. The company also secured key regulatory approvals and completed a rights issue.
Infibeam Avenues Shatters Records! 93% Revenue Surge & AI Fintech Leap – HUGE Investor News!

Stocks Mentioned:

Infibeam Avenues Ltd
Rediff.com India Ltd

Detailed Coverage:

Infibeam Avenues Ltd announced its strongest quarterly performance, achieving INR 1,964.9 crore in gross revenue, a 93% year-over-year increase for the quarter ending September 30, 2025. Profit After Tax (PAT) margin saw a 42% climb to INR 64.9 crore. The surge was fueled by increased adoption of its digital payment platforms, a 33% year-over-year rise in Total Payment Volume (TPV) to INR 1172 billion, and aggressive merchant acquisition. Key sectors contributing to growth include utilities, recharge, travel, entertainment, and services. Chairman and Managing Director Vishal Mehta highlighted the success of its AI-led digital payment transformation and its positioning to cross USD 1 billion annual revenue run rate. The company sold its Platform Business to subsidiary Rediff.com India Ltd for INR 800 crore. Infibeam retains over 80% equity in Rediff, which will now focus on AI-first commerce, content, and digital services, creating an integrated merchant-consumer digital ecosystem leveraging Rediff's user base and Infibeam's CCAvenue payment platform. Infibeam launched PayCentral.AI, India's first agentic payments platform. It also received in-principle approvals from the Reserve Bank of India (RBI) for a Prepaid Payment Instrument license and from the International Financial Services Centres Authority (IFSCA) to operate as a Payment Service Provider at GIFT-IFSC. The company successfully completed a INR 700 crore rights issue, which was oversubscribed by 1.4 times. Impact: This news significantly impacts Infibeam Avenues Ltd's stock performance and investor sentiment due to its record results and strong strategic execution. The fintech sector in India will also note this success. Impact Rating: 8/10

Difficult Terms: Gross Revenue: The total income generated from sales before deducting any costs or returns. PAT Margin: Profit After Tax Margin, which is the profit remaining after all expenses and taxes have been deducted, expressed as a percentage of revenue. TPV (Total Payment Volume): The total value of all payments processed through a company's platform over a specific period. AI-led: Using Artificial Intelligence to drive processes, decisions, or services. Agentic Payments Platform: A payment platform that uses AI agents to automate and optimize payment processes. Prepaid Payment Instrument (PPI) License: A license from the RBI to issue instruments like digital wallets or prepaid cards. IFSCA: International Financial Services Centres Authority, a regulatory body for financial services in India's International Financial Services Centres (like GIFT City). GIFT-IFSC: Gujarat International Finance Tec-City, an International Financial Services Centre in India. Rights Issue: An offer by a company to issue new shares to its existing shareholders, usually at a discount.


Aerospace & Defense Sector

India's Space Race Ignites! Trishul Space Secures ₹4 Cr for Revolutionary Rocket Engines!

India's Space Race Ignites! Trishul Space Secures ₹4 Cr for Revolutionary Rocket Engines!

India-Germany Drone AI Powerhouse! Zuppa Joins Forces with Eighth Dimension for Future Warfare & Industry!

India-Germany Drone AI Powerhouse! Zuppa Joins Forces with Eighth Dimension for Future Warfare & Industry!

Massive ₹2100 Cr Deal Unlocks Army's SECRET Weapon! India's Defence Just Leveled Up!

Massive ₹2100 Cr Deal Unlocks Army's SECRET Weapon! India's Defence Just Leveled Up!

India's Space Race Ignites! Trishul Space Secures ₹4 Cr for Revolutionary Rocket Engines!

India's Space Race Ignites! Trishul Space Secures ₹4 Cr for Revolutionary Rocket Engines!

India-Germany Drone AI Powerhouse! Zuppa Joins Forces with Eighth Dimension for Future Warfare & Industry!

India-Germany Drone AI Powerhouse! Zuppa Joins Forces with Eighth Dimension for Future Warfare & Industry!

Massive ₹2100 Cr Deal Unlocks Army's SECRET Weapon! India's Defence Just Leveled Up!

Massive ₹2100 Cr Deal Unlocks Army's SECRET Weapon! India's Defence Just Leveled Up!


Healthcare/Biotech Sector

Concord Biotech's Profit PLUMMETS 33%, but HUGE Biotech Acquisition & Green Energy Push Could Spark Comeback!

Concord Biotech's Profit PLUMMETS 33%, but HUGE Biotech Acquisition & Green Energy Push Could Spark Comeback!

Rainbow Children's Medicare Q2 Profit Drops! Revenue Climbs Amidst Major Leadership Change – Investors Must See This!

Rainbow Children's Medicare Q2 Profit Drops! Revenue Climbs Amidst Major Leadership Change – Investors Must See This!

Zydus Lifesciences Bags FDA Green Light for Major US Multiple Sclerosis Drug Launch!

Zydus Lifesciences Bags FDA Green Light for Major US Multiple Sclerosis Drug Launch!

Akums Profit PLUMMETS 36%! Pharma Giant's Global Expansion Gamble - What Investors Must Know!

Akums Profit PLUMMETS 36%! Pharma Giant's Global Expansion Gamble - What Investors Must Know!

Marksans Pharma Q2 Results: Profit Climbs 1.5%, Revenue Soars 12% Amidst Global Expansion!

Marksans Pharma Q2 Results: Profit Climbs 1.5%, Revenue Soars 12% Amidst Global Expansion!

Concord Biotech's Profit PLUMMETS 33%, but HUGE Biotech Acquisition & Green Energy Push Could Spark Comeback!

Concord Biotech's Profit PLUMMETS 33%, but HUGE Biotech Acquisition & Green Energy Push Could Spark Comeback!

Rainbow Children's Medicare Q2 Profit Drops! Revenue Climbs Amidst Major Leadership Change – Investors Must See This!

Rainbow Children's Medicare Q2 Profit Drops! Revenue Climbs Amidst Major Leadership Change – Investors Must See This!

Zydus Lifesciences Bags FDA Green Light for Major US Multiple Sclerosis Drug Launch!

Zydus Lifesciences Bags FDA Green Light for Major US Multiple Sclerosis Drug Launch!

Akums Profit PLUMMETS 36%! Pharma Giant's Global Expansion Gamble - What Investors Must Know!

Akums Profit PLUMMETS 36%! Pharma Giant's Global Expansion Gamble - What Investors Must Know!

Marksans Pharma Q2 Results: Profit Climbs 1.5%, Revenue Soars 12% Amidst Global Expansion!

Marksans Pharma Q2 Results: Profit Climbs 1.5%, Revenue Soars 12% Amidst Global Expansion!